FOTO: Five Consecutive Days on Treatment With Efavirenz, Tenofovir, and Emtricitabine Followed by Two Days Off Treatment Versus Continuous Treatment

• Status: Completed
• Trial end date: 2009-12-01
• Target enrollment: 0
• Participant gender: All

Summary

For people with HIV who are currently taking specific medications (including Sustiva (efavirenz)) and have no detectable viral load, this study tracks how patients do if they take their medications for five days of the week compared with seven days of the week.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Community Research Initiative of New England
• Collaborator: The Campbell Foundation
• Treatments: Efavirenz; Emtricitabine; Tenofovir

Criteria

Inclusion Criteria:

• Age 18 years or older

• CD4 count > or = 200

• Viral load < 50

• Treatment with a regimen containing efavirenz and tenofovir and lamivudine or emtricitabine for at least 90 days prior to screening

Exclusion Criteria:

• Detectable HIV RNA on an ultrasensitive assay within the 90 days preceding screening

• Prior evidence of intermediate or high level resistance to efavirenz, tenofovir or cytidine analogues

• Hepatitis B infection